TCI Peptide Therapeutics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $5.02M
Latest Deal Amount
  • Investors
  • 5

TCI Peptide Therapeutics General Information

Description

Developer of therapeutics intended to help create drugs for the treatment of cachexia. The company's drugs are melanocortin based peptide drugs for treating cardiovascular problems which are free from any adverse cardiovascular side effects, enabling healthcare practitioners to use these drugs for proper treatment of cancer and other chronic diseases.

Contact Information

Formerly Known As
Tensive Controls
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1601 South Providence Road
  • Columbia, MO 65211
  • United States
+1 (573) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TCI Peptide Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jun-2017 $5.02M 00.000 Completed Generating Revenue
4. Later Stage VC (Series A) 01-Jun-2016 00.000 00.000 Completed Generating Revenue
3. Grant 01-Jan-2014 0000 Completed Generating Revenue
2. Grant 01-Jan-2012 $1.75M Completed Startup
1. Early Stage VC Completed Startup
To view TCI Peptide Therapeutics’s complete valuation and funding history, request access »

TCI Peptide Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Jake Halliday Ph.D Chief Executive Officer & Chairman
Kenneth Gruber Ph.D Founder, President & Chief Scientific Officer
LeAnn Qi Chief Commercial Officer
Michael Callahan Ph.D Vice President
To view TCI Peptide Therapeutics’s complete executive team members history, request access »

TCI Peptide Therapeutics Board Members (1)

Name Representing Role Since
Jake Halliday Ph.D TCI Peptide Therapeutics Chief Executive Officer & Chairman 000 0000
To view TCI Peptide Therapeutics’s complete board members history, request access »

TCI Peptide Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TCI Peptide Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Centennial Investors Angel Group Minority 000 0000 000000 0
United States Department of Agriculture Government 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Missouri Technology Corporation Venture Capital Minority 000 0000 000000 0
To view TCI Peptide Therapeutics’s complete investors history, request access »